Balchem (BCPC) Q4 2023 earnings summary

Executive summary

• FY2023 sales declined 2.1% to $922.4M; reported net income rose 3.0% to $108.5M and adjusted EBITDA reached a record $230.9M, up 7.1%.

• Q4 adjusted EBITDA rose 5.4% to a record $55.4M; net income increased 24.5% to $26.6M, and free cash flow reached a record $56.0M.

• Strategic priorities include organic growth, innovation, market expansion, targeted M&A, margin strength, and cash conversion.

Financial highlights

• Q4 sales were $228.7M versus $232.5M; gross margin was $75.0M versus $68.6M, and operating earnings were $38.3M versus $33.3M.

• Q4 GAAP diluted EPS was $0.82 versus $0.66; adjusted diluted EPS was $0.95 versus $0.94.

• FY2023 GAAP diluted EPS was $3.35 versus $3.25; adjusted diluted EPS was $4.00 versus $4.03, and adjusted net earnings were $129.7M versus $130.5M.

• FY2023 reported EBITDA was $213.8M versus $196.7M.

Outlook and guidance

• Management expects full-year 2024 top- and bottom-line growth while advancing strategic growth initiatives.

• Growth initiatives include choline and Vitamin K2, mineral nutrition systems, microencapsulation, rumen-protected nutrients, pet and aquaculture markets, and plant micronutrients.

• Plans combine new products, geographic expansion, market penetration, adjacent capabilities, and targeted M&A, while maintaining margins, cash conversion, and a solid balance sheet.